よむ、つかう、まなぶ。
資料３－２ ヒドロキシエチルデンプン調査結果報告書 (22 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_29975.html |
| 出典情報 | 薬事・食品衛生審議会 薬事分科会医薬品等安全対策部会安全対策調査会（令和4年度第22回 12／27）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
禁忌
カナダ
HES130（VOLUVEN）
VOLUVEN is contraindicated in patients:
➢ with fluid overload (hyperhydration), especially in cases of
pulmonary edema and
congestive cardiac failure.
➢ with sepsis.
➢ with renal impairment with oliguria or anuria not related to
hypovolemia.
➢ with critical illness (typically admitted to the intensive care unit).
➢ with severe liver disease.
➢ receiving dialysis treatment.
➢ with severe hypernatremia or severe hyperchloremia.
➢ with known hypersensitivity to hydroxyethyl starch.
➢ with intracranial bleeding.
➢ with pre-existing coagulation or bleeding disorders.
22
オーストラリア
HES130（VOLUVEN）
Voluven should not be used, if any one or more of the following clinical
conditions apply:
• Critically ill patients (typically admitted to intensive care unit),
including those with sepsis
• Fluid overload (hyperhydration), especially in cases of pulmonary
oedema and congestive cardiac failure
• Patients with pre-existing coagulation or bleeding disorders
• Renal failure with oliguria or anuria not related to hypovolaemia
• Patients receiving dialysis treatment
• Intracranial bleeding
• Severe hypernatraemia or severe hyperchloraemia
• Known hypersensitivity to hydroxyethyl starches
• Patients with severe liver disease
カナダ
HES130（VOLUVEN）
VOLUVEN is contraindicated in patients:
➢ with fluid overload (hyperhydration), especially in cases of
pulmonary edema and
congestive cardiac failure.
➢ with sepsis.
➢ with renal impairment with oliguria or anuria not related to
hypovolemia.
➢ with critical illness (typically admitted to the intensive care unit).
➢ with severe liver disease.
➢ receiving dialysis treatment.
➢ with severe hypernatremia or severe hyperchloremia.
➢ with known hypersensitivity to hydroxyethyl starch.
➢ with intracranial bleeding.
➢ with pre-existing coagulation or bleeding disorders.
22
オーストラリア
HES130（VOLUVEN）
Voluven should not be used, if any one or more of the following clinical
conditions apply:
• Critically ill patients (typically admitted to intensive care unit),
including those with sepsis
• Fluid overload (hyperhydration), especially in cases of pulmonary
oedema and congestive cardiac failure
• Patients with pre-existing coagulation or bleeding disorders
• Renal failure with oliguria or anuria not related to hypovolaemia
• Patients receiving dialysis treatment
• Intracranial bleeding
• Severe hypernatraemia or severe hyperchloraemia
• Known hypersensitivity to hydroxyethyl starches
• Patients with severe liver disease